Top

Published in:

01-01-2009 | Clinical study - patient study

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma

Authors: Francesca Valcamonico, Vittorio Ferrari, Vito Amoroso, Giovanni Rangoni, Edda Simoncini, Patrizia Marpicati, Lucia Vassalli, Salvatore Grisanti, Giovanni Marini

Published in: Journal of Neuro-Oncology | Issue 1/2009

Abstract

We report the case of a 75-year old woman who received sorafenib (Nexavar^®, Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.

Cohen H, McGovern F (2005) Renal Cell carcinoma. N Engl J Med 353:3477–3490

Flanigan RC, Mickisch G, Sylvester R et al (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071–1076. doi:10.1097/01.ju.0000110610.61545.ae PubMedCrossRef

Gerstner ER, Fine RL (2007) Increased permeability of the blood–brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25(16):2306–2312. doi:10.1200/JCO.2006.10.0677 PubMedCrossRef

Costa LJ, Drabkin HA (2007) Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12:1404–1415. doi:10.1634/theoncologist.12-12-1404 PubMedCrossRef

Chang YS, Henderson A, Xue D et al (2005) BAY 43-9006 (Sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. Proc Am Assoc Cancer Res: 46. Abstract

Strumberg D, Clark JW, Awada A et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426–437. doi:10.1634/theoncologist.12-4-426 PubMedCrossRef

Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512. doi:10.1200/JCO.2005.03.6723 PubMedCrossRef

Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463. doi:10.1200/JCO.2004.06.132 PubMedCrossRef

Bracarda S, Caserta C, Sordini L et al (2007) Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Ann Oncol 18(Suppl 6):vi22–vi25. doi:10.1093/annonc/mdm219 PubMedCrossRef

10.

Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109. doi:10.1158/0008-5472.CAN-04-1443 PubMedCrossRef

11.

Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875. doi:10.1056/NEJM199609193351207 PubMedCrossRef

12.

Ratain MJ, Eisen T, Stadler WM et al (2006) Phase II placebo-controlled randomised discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512. doi:10.1200/JCO.2005.03.6723 PubMedCrossRef

13.

Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134. doi:10.1056/NEJMoa060655 PubMedCrossRef

14.

Massard C, Zonierek J, Laplanche A et al (2006) Incidence of brain metastasis in advanced renal cell carcinoma among patients randomised in a phase III trial of sorafenib, an oral multi-kinase inhibitor. Ann Oncol 17:148–149 (suppl 9, abstr 454P)CrossRef

15.

Medioni J, Cojocarasu O, Belcaceres JL et al (2007) Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 18(7):1282–1283. doi:10.1093/annonc/mdm275 PubMedCrossRef

16.

Trinh QD, Cardinal E, Gallina A et al (2006) Sunitinib relieves renal cell carcinoma spinal cord compression. Eur Urol 51(6):1741–1743. doi:10.1016/j.eururo.2006.10.050 PubMedCrossRef

Title: Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma
Authors: Francesca Valcamonico
Vittorio Ferrari
Vito Amoroso
Giovanni Rangoni
Edda Simoncini
Patrizia Marpicati
Lucia Vassalli
Salvatore Grisanti
Giovanni Marini
Publication date: 01-01-2009
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2009
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-008-9676-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

A de novo desmoid tumor of the surgical site following foramen magnum meningioma resection in a patient with Gardner’s Syndrome: a case report and review of the literature

Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy

Myeloid sarcoma presenting as a recurrent, multifocal nerve root entrapment syndrome

Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis?

Surgical resection and permanent iodine-125 brachytherapy for brain metastases

Asymptomatic cerebellopontine angle and lateral ventricle metastases from renal cell carcinoma: case report and literature review